IP Library Assignment 040575/0110
Patent Assignment
Reel/Frame 040575/0110

Security Interest

Recorded: 2016-11-07 Pages: 212
Assignor
OMEROS CORPORATION
Executed: 2016-11-03
Assignee
CRG SERVICING LLC, AS ADMINISTRATIVE AGENT
1000 MAIN STREET, SUITE 2500, HOUSTON, TEXAS, 77002
Covered Properties (123)
Inducible Mutagenesis of Target Genes
Patent: 9,815,885 →
Application: 14/998,134 →
Publication: US US20160201053A1
Composition and Method for Diversification of Target Sequences
Patent: 9,677,070 →
Application: 13/802,255 →
Publication: US US20130261012A1
Anti-FZD10 Monoclonal Antibodies and Methods for Their Use
Patent: 9,777,065 →
Application: 14/789,612 →
Publication: US US20160333107A1
Monoclonal Antibodies, Compositions and Methods for Detecting Mucin-like Protein (MLP) as a Biomarker for Ovarian and Pancreatic Cancer
Application: 62/347,824 →
Mixed Micelles
Patent: 9,655,981 →
Application: 15/048,098 →
Publication: US US20160228580A1
Methods and Compositions Related to Mutant Kunitz Domain I of Tfpi-2
Application: 14/615,355 →
Publication: US US20150191528A1
Human Kunitz-Type Inhibitor with Enhanced Antifibrinolytic Activity
Patent: 7,585,842 →
Application: 11/646,776 →
Publication: US US20080026998A1
Dual Reactivity Potent Kunitz Inhibitor of Fibrinolysis
Application: 14/213,828 →
Publication: US US20140288000A1
Genetically Modified Non-Human Mammals and Cells
Application: 14/316,235 →
Publication: US US20150067897A1
Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation
Application: 15/334,081 →
Publication: US US20170233493A1
Methods for Treating Disseminated Intravascular Coagulation by Inhibiting MASP-2 Dependent Complement Activation
Application: 14/168,785 →
Publication: US US20140205598A1
Methods for Treating Conditions Associated with Masp-2 Dependent Complement Activation
Application: 14/459,656 →
Publication: US US20150064176A1
Compositions for Inhibiting Masp-2 Dependent Complement Activation
Application: 15/263,876 →
Publication: US US20170088632A1
MASP-2, A Complement Fixing Enzyme, and Uses for It
Application: 15/227,479 →
Publication: US US20170037150A1
Antibodies to Masp-2
Application: 14/745,247 →
Publication: US US20160096897A1
Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation
Application: 14/581,191 →
Publication: US US20150239985A1
Methods for Identifying Inhibitors of Mannan-Binding Lectin-Associated Serine Protease (Masp) Proteins and Uses Thereof
Patent: 9,724,314 →
Application: 14/310,242 →
Publication: US US20140364507A1
Compositions and Methods of Inhibiting MASP-1 and/or MASP-2 and/or MASP-3 for the Treatment of Paroxysmal Nocturnal Hemoglobinuria
Application: 13/857,391 →
Publication: US US20130273053A1
Methods of Generating Bioactive Peptide-bearing Antibodies and Compositions Comprising the Same
Application: 14/207,143 →
Publication: US US20140363433A1
Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation
Application: 13/790,756 →
Publication: US US20140056873A1
Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation
Application: 15/093,067 →
Publication: US US20160272727A1
Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation
Patent: 9,644,035 →
Application: 13/830,831 →
Publication: US US20130266560A1
Compositions and Methods of Inhibiting MASP-1 and/or MASP-2 and/or MASP-3 for the Treatment of Various Diseases and Disorders
Application: 13/921,139 →
Publication: US US20130344073A1
Methods for Inhibiting Fibrosis in a Subject in Need Thereof
Application: 62/275,025 →
Methods of Generating Bioactive Peptide-bearing Antibodies and Compositions Comprising the Same
Application: 14/213,630 →
Publication: US US20150017162A1
Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation
Application: 14/517,750 →
Publication: US US20150166675A1
Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation
Application: 14/517,761 →
Publication: US US20150166676A1
Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation
Application: 62/252,814 →
Methods for Inhibiting Angiogenesis in a Subject in Need Thereof
Application: 62/315,857 →
Highly Concentrated Low Viscosity Masp-2 Inhibitory Antibody Formulations, Kits, and Methods
Application: 62/382,156 →
Compositions and Methods of Inhibiting MASP-3 for the Treatment of Various Diseases and Disorders
Application: 62/369,674 →
Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation
Application: 62/406,726 →
Methods for Inhibiting Fibrosis in a Subject in Need Thereof
Application: 62/407,979 →
PDE10 Inhibitors and Related Compositions and Methods
Patent: 9,783,521 →
Application: 13/742,199 →
Publication: US US20140038951A1
PDE10 Inhibitors and Related Compositions and Methods
Application: 15/229,020 →
Publication: US US20170152238A1
Processes and Intermediates for the Preparation of a PDE10 Inhibitor
Patent: 9,650,368 →
Application: 14/696,287 →
Publication: US US20160024069A1
Solid State Forms of a PDE10 Inhibitor
Application: 62/251,074 →
PDE10 Inhibitors and Related Compositions and Methods
Patent: 9,879,002 →
Application: 15/136,699 →
Publication: US US20170022190A1
Optically Active PDE10 Inhibitor
Patent: 9,493,447 →
Application: 14/696,295 →
Publication: US US20160024070A1
Optically Active PDE10 Inhibitor
Patent: 9,850,238 →
Application: 15/291,948 →
Publication: US US20170096420A1
Use of PDE7 Inhibitors for the Treatment of Movement Disorders
Application: 12/974,693 →
Publication: US US20110091388A1
Treatment of Addiction and Impulse-Control Disorders Using PDE7 Inhibitors
Application: 13/290,868 →
Publication: US US20120115849A1
Treatment of Addiction and Impulse-Control Disorders Using PDE7 Inhibitors
Application: 14/960,750 →
Publication: US US20160158247A1
G Protein Coupled Receptors and Uses Thereof
Application: 15/007,805 →
Publication: US US20160282365A1
G Protein Coupled Receptors and Uses Thereof
Application: 14/633,554 →
Publication: US US20160219845A1
Method of Identifying Transmembrane Protein-interacting Compounds
Application: 14/657,754 →
Publication: US US20150377896A1
Arthroscopic irrigation solution and method for peripheral vasoconstriction and inhibition of pain and inflammation
Application: 14/984,031 →
Publication: US US20160184272A1
Arthroscopic Irrigation Solution and Method for Peripheral Vasoconstriction and Inhibition of Pain and Inflammation
Application: 14/933,633 →
Publication: US US20160067219A1
Arthroscopic Irrigation Solution and Method for Peripheral Vasoconstriction and Inhibition of Pain and Inflammation
Application: 14/937,002 →
Publication: US US20160120846A1
Ophthalmologic Irrigation Solutions and Method
Patent: 9,585,895 →
Application: 14/946,435 →
Publication: US US20160106761A1
Ophthalmologic Irrigation Solutions and Method
Application: 15/198,208 →
Publication: US US20170100412A1
Cyclooxygenase Inhibitor and Calcium Channel Antagonist Compositions and Methods for Use in Urological Procedures
Application: 14/947,107 →
Publication: US US20160166555A1
Cyclooxygenase Inhibitor and Calcium Channel Antagonist Compositions and Methods for Use in Urological Procedures
Patent: 9,855,256 →
Application: 15/145,453 →
Publication: US US20160317515A1
Stable Anti-inflammatory Solutions for Injection
Application: 14/971,154 →
Publication: US US20160166696A1
Stable Preservative-Free Mydriatic and Anti-Inflammatory Solutions for Injection
Patent: 9,855,246 →
Application: 15/278,514 →
Publication: US US20170196838A1
Anti-Inflammatory and Mydriatic Intracameral Solutions for Inhibition of Postoperative Ocular Inflammatory Conditions
Application: 14/953,806 →
Publication: US US20160279099A1
Compositions and Methods for Prophylaxis and Treatment of Addictions
Application: 12/722,429 →
Publication: US US20160331729A9
Compositions and Methods for Prophylaxis and Treatment of Addictions
Application: 15/231,239 →
Publication: US US20170027920A1
Andrographis Paniculata Compositions and Methods for Treatment of Addictions
Application: 13/934,659 →
Publication: US US20140072662A1
B Cells Modified to Reversibly Induce Accelerated Mutagenesis of Target Genes
Patent: 8,679,845 →
Application: 12/598,031 →
Publication: US US20100093033A1
Inducible Mutagenesis of Target Genes
Patent: 9,273,119 →
Application: 14/173,710 →
Publication: US US20150322134A1
Generation of Anti-FN14 Monoclonal Antibodies by Ex-Vivo Accelerated Antibody Evolution
Patent: 8,609,818 →
Application: 13/416,752 →
Publication: US US20120258121A1
Generation of Anti-FN14 Monoclonal Antibodies by Ex-Vivo Accelerated Antibody Evolution
Patent: 9,346,888 →
Application: 14/080,249 →
Publication: US US20140178385A1
Anti-FZD10 Monoclonal Antibodies and Methods for Their Use
Patent: 9,102,724 →
Application: 13/571,151 →
Publication: US US20130095104A1
Compositions and Methods for Systemic Inhibition of Cartilage Degradation
Patent: 7,067,144 →
Application: 10/356,649 →
Publication: US US20030235589A1
Injectable Drug Delivery Systems with Cyclodextrin-Polymer Based Hydrogels
Patent: 8,003,125 →
Application: 09/861,182 →
Publication: US US20020019369A1
Biodegradable Triblock Copolymers, Synthesis Methods Therefore, and Hydrogels and Biomaterials Made There From
Patent: 7,297,348 →
Application: 10/624,136 →
Publication: US US20040072799A1
Mixed Micelles
Patent: 9,295,685 →
Application: 13/403,382 →
Publication: US US20120225017A1
Soft Tissue Repair System
Patent: 8,006,700 →
Application: 10/114,709 →
Publication: US US20020169477A1
Tendon Repair Using Adhesive
Patent: 6,740,100 →
Application: 10/112,597 →
Publication: US US20020161400A1
Methods and Compositions Related to Mutant Kunitz Domain I of Tfpi-2
Patent: 8,993,719 →
Application: 12/087,296 →
Publication: US US20090018069A1
Genetically Modified Non-Human Mammals and Cells
Patent: 8,785,717 →
Application: 11/570,087 →
Publication: US US20090205058A1
Methods for Treating Conditions Associated with Masp-2 Dependent Complement Activation
Patent: 7,919,094 →
Application: 11/645,359 →
Publication: US US20070172483A1
Methods for Treating Disseminated Intravascular Coagulation by Inhibiting Masp-2 Dependent Complement Activation
Patent: 8,652,477 →
Application: 12/905,972 →
Publication: US US20110091450A1
Methods for Treating Conditions Associated with Masp-2 Dependent Complement Activation
Patent: 8,840,893 →
Application: 13/083,441 →
Publication: US US20110311549A1
Compositions for Inhibiting Masp-2 Dependent Complement Activation
Patent: 9,011,860 →
Application: 13/464,334 →
Publication: US US20120282263A1
Compositions for Inhibiting Masp-2 Dependent Complement Activation
Patent: 9,475,885 →
Application: 14/660,040 →
Publication: US US20160002349A1
Masp-2, a Complement-Fixing Enzyme, and Uses for It
Patent: 6,969,601 →
Application: 09/874,198 →
Publication: US US20020082208A1
Masp-2, a Complement-Fixing Enzyme, and Uses for It
Patent: 7,083,786 →
Application: 09/874,238 →
Publication: US US20020082209A1
Masp-2, a Complement-Fixing Enzyme, and Uses for It
Patent: 7,060,267 →
Application: 11/032,149 →
Publication: US US20050158297A1
Masp 2, a Complement-Fixing Enzyme, and Uses for It
Patent: 8,551,790 →
Application: 13/359,348 →
Publication: US US20120219965A1
Masp-2, a Complement Fixing Enzyme, and Uses for It
Patent: 9,441,262 →
Application: 14/031,377 →
Publication: US US20140134641A1
Antibodies to Masp-2
Patent: 9,096,676 →
Application: 10/556,509 →
Publication: US US20070009528A1
Masp-2,A Complement-Fixing Enzyme, and Uses for It
Patent: 7,112,414 →
Application: 10/332,713 →
Publication: US US20040038297A1
Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation
Patent: 8,951,522 →
Application: 13/441,827 →
Publication: US US20120258095A1
Methods for Identifying Inhibitors of Mannan-Binding Lectin Associated Serine Protease (Masp) Proteins and Uses Thereof
Patent: 8,795,973 →
Application: 13/306,874 →
Publication: US US20120225437A1
PDE10 Inhibitors and Related Compositions and Methods
Patent: 7,786,139 →
Application: 12/124,051 →
Publication: US US20080300240A1
PDE10 Inhibitors and Related Compositions and Methods
Patent: 8,278,327 →
Application: 12/848,766 →
Publication: US US20110021509A1
PDE10 Inhibitors and Related Compositions and Methods
Patent: 8,377,930 →
Application: 12/535,598 →
Publication: US US20100035872A1
PDE10 Inhibitors and Related Compositions and Methods
Patent: 8,343,970 →
Application: 13/045,162 →
Publication: US US20110224202A1
PDE10 Inhibitors and Related Compositions and Methods
Patent: 8,685,975 →
Application: 13/679,818 →
Publication: US US20130196994A1
PDE10 Inhibitors and Related Compositions and Methods
Patent: 9,102,643 →
Application: 14/177,952 →
Publication: US US20140228581A1
PDE10 Inhibitors and Related Compositions and Methods
Patent: 9,434,707 →
Application: 14/601,100 →
Publication: US US20150133675A1
Use of PDE7 Inhibitors for the Treatment of Movement Disorders
Patent: 8,637,528 →
Application: 12/435,347 →
Publication: US US20100113486A1
Use of PDE7 Inhibitors for the Treatment of Movement Disorders
Patent: 9,119,822 →
Application: 14/106,206 →
Publication: US US20140179717A1
1,3,5-Trisubstituted-5-Phenyl and 5-Pyridyl Pyrazolopyrimidinone Derivatives Having PDE7 Inhibiting Action
Patent: 7,268,128 →
Application: 10/866,198 →
Publication: US US20050148604A1
Thienopyrazole Derivative Having PDE7 Inhibitory Activity
Patent: 7,932,250 →
Application: 11/630,757 →
Publication: US US20090131413A1
Thienopyrazole Derivative Having PDE7 Inhibitory Activity
Patent: 8,901,315 →
Application: 14/013,168 →
Publication: US US20140073799A1
Treatment of Addiction and Impulse-Control Disorders Using PDE7 Inhibitors
Patent: 9,220,715 →
Application: 13/835,607 →
Publication: US US20130267502A1
Method of Identifying a Compound for the Treatment or Prevention of Obesity
Patent: 8,999,654 →
Application: 12/916,227 →
Publication: US US20110214189A1
Method of Identifying Transmembrane Protein-Interacting Compounds
Patent: 7,309,576 →
Application: 10/509,787 →
Publication: US US20050287602A1
Method of Identifying Transmembrane Protein-Interacting Compounds
Patent: 7,794,955 →
Application: 11/937,275 →
Publication: US US20090081691A1
Method of Identifying Transmembrane Protein-Interacting Compounds
Patent: 8,298,777 →
Application: 12/834,351 →
Publication: US US20100279318A1
Method of Identifying Transmembrane Protein-Interacting Compounds
Patent: 9,005,905 →
Application: 13/626,294 →
Publication: US US20130084581A1
Vectors and Methods for the Mutagenesis of Mammalian Genes
Patent: 6,228,639 →
Application: 09/002,046 →
Vectors and Methods for the Mutagenesis of Mammalian Genes
Patent: 8,389,795 →
Application: 10/974,603 →
Publication: US US20050059078A1
Method of Inhibition of Pain and Inflammation During Surgery Comprising Administration of Soluble Tnf Receptors
Patent: 7,091,181 →
Application: 09/839,633 →
Publication: US US20020028798A1
Arthroscopic irrigation solution and method for peripheral vasoconstriction and inhibiton of pain and inflammation
Patent: 9,254,271 →
Application: 12/384,781 →
Publication: US US20090253795A1
Arthroscopic Irrigation Solution and Method for Peripheral Vasoconstriction and Inhibition of Pain and Inflammation
Patent: 7,973,068 →
Application: 10/138,192 →
Publication: US US20030096807A1
Arthroscopic Irrigation Solution and Method for Peripheral Vasoconstriction and Inhibition of Pain and Inflammation
Patent: 8,450,309 →
Application: 13/047,386 →
Publication: US US20110160195A1
Ophthalmologic Irrigation Solutions and Method
Patent: 8,173,707 →
Application: 12/799,981 →
Publication: US US20100311705A1
Ophthalmologic Irrigation Solutions and Method
Patent: 8,586,633 →
Application: 13/420,456 →
Publication: US US20130065869A1
Ophthalmologic Irrigation Solutions and Method
Patent: 9,399,040 →
Application: 14/075,588 →
Publication: US US20140221326A1
Ophthalmologic Irrigation Solutions and Method
Patent: 9,278,101 →
Application: 14/186,146 →
Publication: US US20140235597A1
Cyclooxygenase Inhibitor and Calcium Channel Antagonist Compositions and Methods for Use in Urological Procedures
Patent: 8,790,696 →
Application: 11/384,235 →
Publication: US US20060263393A1
Stable Preservative-free Mydriatic and Anti-inflammatory Solutions for Injection
Patent: 9,066,856 →
Application: 14/061,039 →
Publication: US US20140235691A1
Stable Preservative-free Mydriatic and Anti-inflammatory Solutions for Injection
Patent: 9,486,406 →
Application: 14/721,151 →
Publication: US US20150342928A1
Compositions and Methods for Prophylaxis and Treatment of Addictions
Patent: 8,426,439 →
Application: 12/101,943 →
Publication: US US20090048232A1
Rotational Intrathecal Analgesia
Patent: 7,737,118 →
Application: 10/187,454 →
Publication: US US20030040486A1
Processes and Intermediates for the Preparation of a PDE10 Inhibitor
PDE10 Inhibitors and Related Compositions and Methods
Optically Active PDE10 Inhibitor
Anti-Inflammatory and Mydriatic Intracameral Solutions for Inhibition of Postoperative Ocular Inflammatory Conditions
Related Assignments (24)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignor's Interest Aug 16, 2013
From: MAIZELS, NANCY
To: UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION
Reel/Frame 031027/0978 →
Assignment of Assignor's Interest Aug 16, 2013
From: ALLISON, DANIEL S.; CUMMINGS, W. JASON; LEPPARD, JOHN B.; TJOELKER, LARRY W.
To: OMEROS CORPORATION
Reel/Frame 031028/0291 →
Corrective Assignment to Correct the 5TH Inventor's Middle Name Previously Recorded on Reel 031028 Frame 0291. Assignor(S) Hereby Confirms the Middle Name of the 5TH Inventor Listed as Louise Should Be Corrected to L. Aug 20, 2013
From: ALLISON, DANIEL S.; CUMMINGS, W. JASON; LEPPARD, JOHN B.; TJOELKER, LARRY W.
To: OMEROS CORPORATION
Reel/Frame 031049/0956 →
Assignment of Assignor's Interest Jan 8, 2014
From: DEMOPULOS, GREGORY A.; DUDLER, THOMAS; OMEROS CORPORATION
To: OMEROS CORPORATION; UNIVERSITY OF LEICESTER
Reel/Frame 031920/0382 →
Assignment of Assignor's Interest Jan 9, 2014
From: DEMOPULOS, GREGORY A.; OMEROS CORPORATION
To: OMEROS CORPORATION; UNIVERSITY OF LEICESTER
Reel/Frame 031931/0691 →
Assignment of Assignor's Interest Feb 25, 2014
From: SCHWAEBLE, HANS-WILHELM; UNIVERSITY OF LEICESTER
To: UNIVERSITY OF LEICESTER; OMEROS CORPORATION
Reel/Frame 032296/0899 →
Assignment of Assignor's Interest Feb 26, 2014
From: TEDFORD, CLARK E.; PARENT, JAMES BRIAN; OMEROS CORPORATION
To: OMEROS CORPORATION; UNIVERSITY OF LEICESTER
Reel/Frame 032306/0934 →
Assignment of Assignor's Interest Feb 26, 2014
From: SCHWAEBLE, HANS-WILHELM; UNIVERSITY OF LEICESTER
To: UNIVERSITY OF LEICESTER; OMEROS CORPORATION
Reel/Frame 032305/0693 →
Assignment of Assignor's Interest Feb 26, 2014
From: SCHWAEBLE, HANS-WILHELM; UNIVERSITY OF LEICESTER
To: UNIVERSITY OF LEICESTER; OMEROS CORPORATION
Reel/Frame 032307/0001 →
Assignment of Assignor's Interest Jun 9, 2014
From: BAJAJ, S. PAUL
To: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Reel/Frame 033108/0004 →
Assignment of Assignor's Interest Sep 15, 2014
From: CUMMINGS, W. JASON; GRAY, PATRICK; TJOELKER, LARRY; YABUKI, MUNEHISA
To: OMEROS CORPORATION
Reel/Frame 033739/0045 →
Assignment of Assignor's Interest Dec 11, 2015
From: LARSEN, FLEMMING; WAHLERS, ULLA
To: HELION BIOTECH APS
Reel/Frame 037277/0605 →
Assignment of Assignor's Interest Mar 11, 2016
From: MAIZELS, NANCY; CUMMINGS, W. JASON; YABUKI, MUNEHISA
To: UNIVERSITY OF WASHINGTON
Reel/Frame 037957/0302 →
Confirmatory License Jun 13, 2016
From: UNIVERSITY OF CALIFORNIA LOS ANGELES
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 038972/0891 →
Confirmatory License Jun 22, 2016
From: UNIVERSITY OF WASHINGTON
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 039113/0495 →
Confirmatory License Jun 23, 2016
From: UNIVERSITY OF CALIFORNIA LOS ANGELES
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 039128/0117 →
Confirmatory License Dec 29, 2016
From: UNIVERSITY OF CALIFORNIA LOS ANGELES
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 041210/0202 →
Assignment of Assignor's Interest Sep 14, 2017
From: SCHWAEBLE, HANS-WILHELM; UNIVERSITY OF LEICESTER
To: OMEROS CORPORATION; UNIVERSITY OF LEICESTER
Reel/Frame 043595/0700 →
Assignment of Assignor's Interest Sep 14, 2017
From: DEMOPULOS, GREGORY A.; OMEROS CORPORATION
To: OMEROS CORPORATION; UNIVERSITY OF LEICESTER
Reel/Frame 043595/0689 →
Assignment of Assignor's Interest Jul 2, 2018
From: MEDICAL RESEARCH COUNCIL
To: UNITED KINGDOM RESEARCH AND INNOVATION
Reel/Frame 046469/0108 →
Release of Security Interest Nov 15, 2018
From: CRG SERVICING LLC
To: OMEROS CORPORATION
Reel/Frame 047573/0577 →
Security Interest Jun 3, 2024
From: OMEROS CORPORATION
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS COLLATERAL AGENT
Reel/Frame 067607/0108 →
Corrective Assignment to Correct the Correct the Box Titled"This Document Serves as an Oath/Declaration (37 Cfr 1.63)" Was Erroneously Checked and This Box Should Not Have Been Checked, Previously Recorded at Reel: 67607 Frame: 108. Assignor(S) Hereby Confirms the Security Interest. Dec 11, 2024
From: OMEROS CORPORATION
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS COLLATERAL AGENT
Reel/Frame 069715/0719 →
Release of Security Interest Nov 25, 2025
From: WILMINGTON SAVINGS FUND SOCIETY, FSB
To: OMEROS CORPORATION
Reel/Frame 073705/0970 →